Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-SERP "50" vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
Hydrochlorothiazide 50 mg orally once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hydrochlorothiazide is not extensively metabolized. Reserpine is metabolized primarily in the liver by CYP450 enzymes.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
90-96% (primarily to albumin and alpha1-acid glycoprotein)
~90%, primarily to albumin
200-400 L/kg (extremely large due to extensive tissue binding, especially in adrenergic nerve terminals)
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 40-50% (extensive first-pass metabolism)
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated in anuria. For GFR 30-60 m L/min: reduce dose to 25 mg daily. For GFR <30 m L/min: not recommended.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B/C: use with caution; monitor electrolytes and renal function; reduce dose if needed.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not typically recommended; safety and efficacy not established.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at 12.5-25 mg orally once daily; titrate cautiously; monitor electrolytes and renal function.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
Electrolyte imbalance (especially hypokalemia),Sulfonamide allergy (hydrochlorothiazide),Mental depression (reserpine),Bradycardia and arrhythmias (reserpine)
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Anuria,Known sulfonamide allergy (hydrochlorothiazide),History of mental depression (reserpine),Active peptic ulcer or ulcerative colitis (reserpine),Electroconvulsive therapy (reserpine)
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-sodium foods (e.g., processed meats, canned soups) to prevent fluid retention and counteract antihypertensive effects. Avoid excessive potassium-rich foods (e.g., bananas, oranges, spinach) as thiazides cause potassium loss; however, reserpine may not affect potassium levels. Limit alcohol intake. Take with food or milk to reduce gastrointestinal upset.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Hydrochlorothiazide: First trimester: Crosses placenta, risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse effects; limited human data, association with congenital anomalies not established. Second and third trimesters: May cause fetal or neonatal electrolyte disturbances, hypoglycemia, and decreased placental perfusion. Reserpine: First trimester: Animal studies show no teratogenic effects, human data insufficient. Second and third trimesters: May cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to depletion of catecholamines.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Hydrochlorothiazide: Excreted into human milk in small amounts; M/P ratio approximately 0.2. Reserpine: Excreted into breast milk; M/P ratio not well established. Both are considered compatible with breastfeeding by most authorities, but use caution as reserpine may cause gastrointestinal disturbances, nasal congestion, and lethargy in the infant. Monitor infant for side effects.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Hydrochlorothiazide: Dose adjustment not typically required for pharmacokinetic changes, but use lowest effective dose due to risk of decreased placental perfusion. Reserpine: No specific dose adjustment recommended for pregnancy. Monitor for hypotension and avoid use near term to reduce neonatal adverse effects.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Hydrochlorothiazide 50 mg plus reserpine 0.125 mg. Monitor serum potassium and magnesium; hypokalemia increases digitalis toxicity risk. Reserpine may cause depression; avoid in patients with history of depression. Onset of antihypertensive effect is 3-6 hours. Use with caution in patients with renal impairment (Cr Cl <30 m L/min) as thiazides are ineffective.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,This drug may make you dizzy; avoid driving or operating machinery until you know how it affects you.,Reserpine can cause nasal congestion, drowsiness, or depression; contact your doctor if you experience mood changes.,Avoid alcohol as it may increase dizziness and drowsiness.,Stay hydrated but do not overhydrate; report excessive thirst, dry mouth, or muscle cramps.,Do not stop taking this medication abruptly as it may cause a rapid increase in blood pressure.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,This medication may increase your sensitivity to sunlight; use sunscreen and protective clothing.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-SERP "50" vs ALDORIL 15, answered by our medical review team.
HYDRO-SERP "50" is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-SERP "50" and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-SERP "50" is: Hydrochlorothiazide 50 mg orally once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-SERP "50" and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-SERP "50" is classified as Category C. Hydrochlorothiazide: First trimester: Crosses placenta, risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse effects; limited human data, association wi. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.